IN THE RIGHT PLACE AT THE RIGHT TIME
Well-positioned to capitalize and contribute
QureTech Bio – fighting bacterial infections and resistance
QureTech Bio address a significant unmet medical need by developing new antibacterial agents that targets different infectious diseases including healthcare-associated infections and tuberculosis. The compounds are new small molecules from a well-developed chemical platform with excellent synthetic availability and desirable drug properties. The company has established a strong IPR portfolio protect these assets.
The company’s lead program is focused on developing a new class of antibiotics (GmPcides) effective against multidrug resistant Gram-positive bacteria. The GmPcides are bactericidal against a broad spectrum of Gram-positive bacteria and no resistance development has been detected in vitro or in clinical isolates. Read more about the GmPcide program here.
The tuberculosis project is developed in partnership with Fimbrion Therapeutics and is supported by Phase I SBIR funding from NIH/NIAID.
Latest News
Contact
We are actively seeking investors and collaboration partners to enable development and commercialization of the company’s pipeline programs.
Welcome to contact us for more information about partnership opportunities.